Aoife Brennan
CIK 1714563 · President and CEO · last filed 2026-06-12
Aoife Brennan is a President and CEO who has filed 30 SEC Form 4 insider transactions across 5 companies since 2018. The most recent filing, for CLYM, was dated Jun 30, 2026. Across all open-market trades the lifetime net is −$139.2K, making them a net seller over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
C/O SYNLOGIC, INC.
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| XLO | Director | — | $7.31 | — | $0 | 3 | 2026-06-12 |
| Climb Bio, Inc. (ELYM) Delisted | President and CEO | 48,132 | $5.11 | $246.0K | -$25.2K | 4 | 2026-01-08 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 1,118 | $9.75 | $10.9K | -$81.4K | 5 | 2024-06-06 |
| SYNLOGIC, INC. (SYBX) Delisted | President and CEO | 17,087 | $0.69 | $11.8K | -$32.7K | 11 | 2023-11-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 3 | 2020-04-03 |
Recent Filings
30 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-30 | CLYM | Notice (144) | −30,902 | -$407.0K | EDGAR |
| 2026-06-12 | XLO | Grant (A) | — | $0 | EDGAR |
| 2026-01-08 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-07-01 | Climb Bio, Inc. (ELYM) Delisted | Mixed | +48,132 | -$25.2K | EDGAR |
| 2025-06-12 | XLO | Grant (A) | — | $0 | EDGAR |
| 2025-01-15 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-27 | Climb Bio, Inc. (ELYM) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-06-17 | XLO | Grant (A) | — | $0 | EDGAR |
| 2024-06-06 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-04-22 | SYNLOGIC, INC. (SYBX) Delisted | Notice (144) | −88,293 | -$161.6K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.